PFIZER LTD (PFIZER): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1Y3YAll

₹3,917.9 latest close · −14.2% over the last 90 sessions

₹3,917.9 month-end · −21.2% over 12 months

₹3,917.9 month-end · −4.1% over 3 years

₹3,917.9 month-end · +29.0% since Jan '19

52-week range ₹3589.00 to ₹5339.00 · 1-year volatility 24.6%

Was the rally earned?

1 year3 years5 years

-21%share price, 1 yearMultiple-driven

Mostly the multiple.

Most of the fall came from investors paying a lower multiple (P/E 49.6x to 39.0x); per-share earnings added 0 points.
The share count barely moved.

Net profit growth0 ptsNet profit was little changed.

P/E change-21 ptsThe P/E fell from 49.6x to 39.0x, which lowers the price.

Share count change0 ptsShare count was little changed. More shares would count against the price.

-4%share price, 3 yearsRoughly flat

The share price was roughly flat over 3 years (-4%).
The share count barely moved.

Net profit growth0 ptsNet profit was little changed.

P/E change-4 ptsThe P/E fell from 40.7x to 39.0x, which lowers the price.

Share count change0 ptsShare count was little changed. More shares would count against the price.

-25%share price, 5 yearsMultiple-driven

Mostly the multiple.

Most of the fall came from investors paying a lower multiple (P/E 51.8x to 39.0x); per-share earnings added 0 points.
The share count barely moved.

Net profit growth0 ptsNet profit was little changed.

P/E change-25 ptsThe P/E fell from 51.8x to 39.0x, which lowers the price.

Share count change0 ptsShare count was little changed. More shares would count against the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-43.6%recovered 2024-09

1-year volatility24.6%annualised

Beta vs sector index0.533-year daily, correlation 0.30

Volume spikes9last 90 sessions, 5x the 50-day median

Drawdown from peak

Largest drawdowns

-43.6% (2021-09 peak to 2023-03 low, recovered 2024-09)

-42.8% (2024-09 peak to 2026-10 low, not yet recovered)

-20.7% (2020-05 peak to 2020-06 low, recovered 2020-09)

Most recent volume spikes

2026-11-03: 14.9x the 50-day median, price +5.0% that day

2026-09-29: 6.7x the 50-day median, price -1.4% that day

2026-09-11: 5.2x the 50-day median, price -0.9% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

39.0xP/E todayWithin its usual range

Against its own history21st percentile

CheapestMedian 43.9xDearest

Usual range 35.4x to 52.8x since 2019-01.

Against Health Technology39.0x vs 37.0x

This company

39.0x

Sector median

37.0x

5% above the Health Technology median.

P/EP/BP/S

P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE86thflat vs a year ago
Revenue growth18th▼ 7 pts vs a year ago
EPS growth37th▼ 4 pts vs a year ago
Debt/equity ↓99thflat vs a year ago
Cash cycle ↓86thflat vs a year ago
P/E ↓46th▲ 16 pts vs a year ago
12M momentum15th▼ 46 pts vs a year ago

Rank history

ROCE

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~30%annual earnings growth implied by the price

At a P/E of 72.1x, the price would imply about 29.9%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Earnings figures have not updated recently, so the company is left out of the lists.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹3917.90
P/E: 39.0x
ROCE: 27.0%
Market Cap: ₹17923 cr
Revenue (TTM): ₹678 cr
P/S: 26.4x
P/B: 19.9x
ROE: 51.0%
Debt / Equity: 0.0x
Promoter Holding: 63.9%
12M Momentum: -21.3%

52-week range

₹3589.00₹5339.00

19% of the way from its 52-week low to its high

Price risk

1Y volatility

24.6%

Beta vs sector

1-year daily

0.69

Balance sheet & cash

Debt service

no meaningful debt

Cash from profit, 3Y

operating cash flow ÷ net profit

0.51x

Share count, 1Y

unchanged

Are profits backed by cash?

3 of 6checks within range2 beyond a threshold

Other income reliance122%Beyond threshold

Other income as a share of pre-tax profit (trailing twelve months): 122.2%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate—Not enough data

Not enough reported data to compute this.

Cash conversion0.51xNear threshold

Operating cash flow divided by net profit over the last three fiscal years: 0.51x (cash from operations ₹378 cr, net profit ₹746 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow3 of 3 yrsWithin range

Fiscal years with positive free cash flow in the last 3: 3. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history0 daysWithin range

Debtor days are below the median of the previous three fiscal years by 0 days (32 vs 32). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress63% of fixed assetsBeyond threshold

Capital work-in-progress is 63% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days0 days / 2 yrsWithin range

Days payable changed by 0 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 2 years, DIIs added 2.7 pts; FIIs trimmed 1.4 pts.
The number of shareholders fell from 1.1 lakh to 1.0 lakh (-9%) between Dec 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupDec '23Jun '26Change

Promoters63.9%63.9%0.0 pts

FIIs3.0%1.6%-1.4 pts

DIIs15.2%17.8%+2.7 pts

Public and others17.9%16.6%-1.3 pts

Number of shareholders

1.0 lakhshareholders-9% since Dec '23

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−4.2%typical 12-month return vs the marketNot meaningfully different from the base rate

We found 50 past situations where a non-financial company looked like PFIZER LTD today on valuation, return on capital, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −24% to +12% vs the market, against −1% for all non-financial companies in the same months.
The gap against the base rate (−3.4%, 80% range −11.0% to +0.8%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 2 beyond the range shown, drawn at the edge

Similar setups' median

−4.2%

All companies' median

−0.8%

Beat the market

40% vs 49%

50 past situations · 50 companies · 32 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
CDSL Finance	Jul 2023	47x	30%	+9%	−13%	+38%
VINATIORGA Process Industries	Aug 2020	31x	—	−5%	−14%	+12%
CLEAN Process Industries	Mar 2025	48x	29%	−12%	−29%	−42%
ICRA Commercial Services	Jul 2020	25x	20%	−23%	−23%	−5%
VSTIND Consumer Non-Durables	Sep 2023	82x	34%	+7%	−10%	−18%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
GILLETTE Consumer Non-Durables	Jan 2021	78x	38%	−10%	−14%	−31%
COHANCE Health Technology	Jan 2024	42x	32%	+37%	−10%	+45%
GLAXO Health Technology	Feb 2024	59x	36%	+63%	−12%	+19%

How reliable is this?

Matched on P/E, P/S, ROCE, debt/equity, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, drawdown from 12-month high and P/E. Not used (unavailable for this company): operating margin and interest cover. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to PFIZER LTD. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

CLEAN SCIENCE AND TECHNOLOGYCLEAN

Process Industries

61%similar

debt/equityrevenue growth

ESAB INDIAESABINDIA

Producer Manufacturing

57%similar

debt/equityrevenue growth

CERA SANITARYWARECERA

Consumer Durables

53%similar

EPS growthrevenue growth

COLGATE-PALMOLIVE (INDIA)COLPAL

Consumer Non-Durables

52%similar

revenue growthEPS growth

VINATI ORGANICSVINATIORGA

Process Industries

52%similar

debt/equityvolatility

PROCTER AND GAMBLE HEALTHPGHL

Health Technology

50%similar

volatilitymarket cap

ALIVUS LIFE SCIENCESALIVUS

Health Technology

47%similar

revenue growthEPS growth

ANTHEM BIOSCIENCESANTHEM

Health Technology

42%similar

ROCEvolatility

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Nov '21

2026
NovPriceVolume reached 14.9x its 50-day median on 2026-11-03; price +5.0% that day.
OctPriceFell 43% from the Sep 2024 peak to the Oct 2026 low.
AugPriceVolume reached 11.8x its 50-day median on 2026-08-20; price +0.0% that day.
JunPriceVolume reached 12.3x its 50-day median on 2026-06-08; price +1.6% that day.
FebPriceVolume reached 77.5x its 50-day median on 2026-02-10; price +4.1% that day.
2025
OctPriceVolume reached 23.0x its 50-day median on 2025-10-01; price +2.3% that day.
AugPriceVolume reached 17.4x its 50-day median on 2025-08-14; price +4.3% that day.
MayValuationP/E crossed above the 90th percentile of its own history to date (55.9x).

Show 22 earlier events

2025
MayPriceVolume reached 69.0x its 50-day median on 2025-05-20; price +10.8% that day.
FebPriceVolume reached 55.2x its 50-day median on 2025-02-24; price +2.4% that day.
2024
DecPriceVolume reached 19.2x its 50-day median on 2024-12-20; price -6.8% that day.
NovValuationP/E crossed above the 90th percentile of its own history to date (52.9x).
SepPriceRegained the 2021-09 peak, 18 months after the low.
JulValuationP/E crossed above the 90th percentile of its own history to date (56.3x).
JulPriceVolume reached 10.8x its 50-day median on 2024-07-10; price +6.5% that day.
JunPeer rankSlipped to the 3rd quartile of Health Technology on EPS growth (from the 2nd quartile).
JunPriceVolume reached 14.2x its 50-day median on 2024-06-21; price -3.6% that day.
FebPriceVolume reached 16.4x its 50-day median on 2024-02-01; price +5.9% that day.
2023
DecPriceVolume reached 9.7x its 50-day median on 2023-12-06; price +0.2% that day.
SepPriceVolume reached 12.9x its 50-day median on 2023-09-07; price +0.0% that day.
JunPriceVolume reached 15.2x its 50-day median on 2023-06-30; price -1.4% that day.
MarPriceFell 44% from the Sep 2021 peak to the Mar 2023 low.
2022
OctPriceVolume reached 13.6x its 50-day median on 2022-10-03; price +0.7% that day.
SepPriceVolume reached 14.6x its 50-day median on 2022-09-06; price +0.8% that day.
JunPeer rankMoved into the top quartile of Health Technology on ROCE (from the 2nd quartile).
MayPriceVolume reached 5.7x its 50-day median on 2022-05-05; price -0.1% that day.
FebPeer rankMoved into the 3rd quartile of Health Technology on EPS growth (from the bottom quartile).
FebPriceVolume reached 7.0x its 50-day median on 2022-02-04; price -2.1% that day.
2021
DecPriceVolume reached 14.1x its 50-day median on 2021-12-14; price +6.2% that day.
NovPeer rankSlipped to the bottom quartile of Health Technology on EPS growth (from the 3rd quartile).

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history95 months · 2019-01 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	39.0x	₹678 cr	51.0%	27.0%	0.0x
2026-10	36.7x	₹678 cr	51.0%	27.0%	0.0x
2026-09	38.6x	₹678 cr	51.0%	27.0%	0.0x
2026-08	46.7x	₹678 cr	51.0%	27.0%	0.0x
2026-07	48.1x	₹678 cr	51.0%	27.0%	0.0x
2026-06	44.2x	₹678 cr	51.0%	27.0%	0.0x
2026-05	45.8x	₹678 cr	51.0%	27.0%	0.0x
2026-04	46.9x	₹678 cr	51.0%	27.0%	0.0x
2026-03	47.0x	₹678 cr	51.0%	27.0%	0.0x
2026-02	50.4x	₹678 cr	51.0%	27.0%	0.0x
2026-01	45.5x	₹678 cr	51.0%	27.0%	0.0x
2025-12	49.7x	₹678 cr	51.0%	27.0%	0.0x
2025-11	49.6x	₹678 cr	51.0%	27.0%	0.0x
2025-10	51.9x	₹678 cr	51.0%	27.0%	0.0x
2025-09	50.2x	₹678 cr	51.0%	27.0%	0.0x
2025-08	51.4x	₹678 cr	51.0%	27.0%	0.0x
2025-07	51.7x	₹678 cr	51.0%	27.0%	0.0x
2025-06	56.6x	₹678 cr	51.0%	27.0%	0.0x
2025-05	55.9x	₹678 cr	51.0%	27.0%	0.0x
2025-04	42.8x	₹678 cr	51.0%	27.0%	0.0x
2025-03	39.9x	₹678 cr	51.0%	27.0%	0.0x
2025-02	40.4x	₹678 cr	51.0%	27.0%	0.0x
2025-01	45.2x	₹678 cr	51.0%	27.0%	0.0x
2024-12	52.6x	₹678 cr	51.0%	27.0%	0.0x
2024-11	52.9x	₹678 cr	51.0%	27.0%	0.0x
2024-10	50.8x	₹678 cr	51.0%	27.0%	0.0x
2024-09	57.0x	₹678 cr	51.0%	27.0%	0.0x
2024-08	60.4x	₹678 cr	51.0%	27.0%	0.0x
2024-07	56.3x	₹678 cr	51.0%	27.0%	0.0x
2024-06	45.1x	₹678 cr	51.0%	27.0%	0.0x
2024-05	45.9x	₹678 cr	51.0%	27.0%	0.0x
2024-04	42.4x	₹678 cr	51.0%	27.0%	0.0x
2024-03	41.8x	₹678 cr	51.0%	27.0%	0.0x
2024-02	45.9x	₹678 cr	51.0%	27.0%	0.0x
2024-01	43.1x	₹678 cr	51.0%	27.0%	0.0x
2023-12	42.5x	₹678 cr	51.0%	27.0%	0.0x
2023-11	40.7x	₹678 cr	51.0%	27.0%	0.0x
2023-10	39.2x	₹678 cr	51.0%	27.0%	0.0x
2023-09	38.4x	₹678 cr	51.0%	27.0%	0.0x
2023-08	38.0x	₹678 cr	51.0%	27.0%	0.0x
2023-07	39.8x	₹678 cr	51.0%	27.0%	0.0x
2023-06	37.6x	₹678 cr	51.0%	27.0%	0.0x
2023-05	37.9x	₹678 cr	51.0%	27.0%	0.0x
2023-04	37.4x	₹678 cr	51.0%	27.0%	0.0x
2023-03	34.5x	₹678 cr	51.0%	27.0%	0.0x
2023-02	37.8x	₹678 cr	51.0%	27.0%	0.0x
2023-01	38.5x	₹678 cr	51.0%	27.0%	0.0x
2022-12	44.1x	₹678 cr	51.0%	27.0%	0.0x
2022-11	45.8x	₹678 cr	51.0%	27.0%	0.0x
2022-10	43.6x	₹678 cr	51.0%	27.0%	0.0x
2022-09	42.5x	₹678 cr	51.0%	27.0%	0.0x
2022-08	41.7x	₹678 cr	51.0%	27.0%	0.0x
2022-07	41.7x	₹678 cr	51.0%	27.0%	0.0x
2022-06	40.6x	₹678 cr	51.0%	27.0%	0.0x
2022-05	43.0x	₹678 cr	51.0%	27.0%	0.0x
2022-04	43.7x	₹678 cr	51.0%	27.0%	0.0x
2022-03	43.3x	₹678 cr	51.0%	27.0%	0.0x
2022-02	43.9x	₹678 cr	51.0%	27.0%	0.0x
2022-01	45.1x	₹678 cr	51.0%	27.0%	0.0x
2021-12	50.4x	₹678 cr	51.0%	27.0%	0.0x
2021-11	51.8x	₹678 cr	51.0%	27.0%	0.0x
2021-10	50.3x	₹678 cr	51.0%	27.0%	0.0x
2021-09	55.6x	₹678 cr	51.0%	27.0%	0.0x
2021-08	57.0x	₹678 cr	51.0%	27.0%	0.0x
2021-07	58.5x	₹678 cr	51.0%	27.0%	0.0x
2021-06	56.5x	₹678 cr	51.0%	27.0%	0.0x
2021-05	51.2x	₹678 cr	51.0%	27.0%	0.0x
2021-04	52.5x	₹678 cr	51.0%	27.0%	0.0x
2021-03	45.1x	₹678 cr	51.0%	27.0%	0.0x
2021-02	45.3x	₹678 cr	51.0%	27.0%	0.0x
2021-01	46.2x	₹678 cr	51.0%	27.0%	0.0x
2020-12	50.9x	₹678 cr	51.0%	27.0%	0.0x
2020-11	50.8x	₹678 cr	51.0%	27.0%	0.0x
2020-10	49.7x	₹678 cr	51.0%	27.0%	0.0x
2020-09	48.8x	₹678 cr	51.0%	27.0%	0.0x
2020-08	45.8x	₹678 cr	51.0%	27.0%	0.0x
2020-07	42.6x	₹678 cr	51.0%	27.0%	0.0x
2020-06	39.5x	₹678 cr	51.0%	27.0%	0.0x
2020-05	40.2x	₹678 cr	51.0%	27.0%	0.0x
2020-04	48.8x	₹678 cr	51.0%	27.0%	0.0x
2020-03	40.1x	₹678 cr	51.0%	27.0%	0.0x
2020-02	41.8x	₹678 cr	51.0%	27.0%	0.0x
2020-01	41.3x	₹678 cr	51.0%	27.0%	0.0x
2019-12	42.1x	₹678 cr	51.0%	27.0%	0.0x
2019-11	41.2x	₹678 cr	51.0%	27.0%	0.0x
2019-10	40.4x	₹678 cr	51.0%	27.0%	0.0x
2019-09	33.4x	₹678 cr	51.0%	27.0%	0.0x
2019-08	29.1x	₹678 cr	51.0%	27.0%	0.0x
2019-07	30.2x	₹678 cr	51.0%	27.0%	0.0x
2019-06	33.4x	₹678 cr	51.0%	27.0%	0.0x
2019-05	31.7x	₹678 cr	51.0%	27.0%	0.0x
2019-04	31.3x	₹678 cr	51.0%	27.0%	0.0x
2019-03	33.1x	₹678 cr	51.0%	27.0%	0.0x
2019-02	32.2x	₹678 cr	51.0%	27.0%	0.0x
2019-01	30.3x	₹678 cr	51.0%	27.0%	0.0x

Methodology and data notes